[1]李松峰,邓光达,刘敬花,等.视网膜下液引流联合玻璃体内注射抗血管内皮生长因子药物治疗重度渗出性视网膜脱离Coats病的临床疗效[J].眼科新进展,2017,37(6):569-571.[doi:10.13389/j.cnki.rao.2017.0144]
　LI Song-Feng,DENG Guang-Da,LIU Jing-Hua,et al.Subretinal fluid drainage combined with intravitreal injection of anti-vascular endothelial growth factor in treatment of severe exudative retinal detachment Coats disease[J].Recent Advances in Ophthalmology,2017,37(6):569-571.[doi:10.13389/j.cnki.rao.2017.0144]
点击复制

视网膜下液引流联合玻璃体内注射抗血管内皮生长因子药物治疗重度渗出性视网膜脱离Coats病的临床疗效/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年6期
页码:
569-571
栏目:
应用研究
出版日期:
2017-06-05

文章信息/Info

Title:
Subretinal fluid drainage combined with intravitreal injection of anti-vascular endothelial growth factor in treatment of severe exudative retinal detachment Coats disease
作者:
李松峰; 邓光达; 刘敬花; 马燕; 卢海
100730　北京市，首都医科大学附属北京同仁医院北京同仁眼科中心
Author(s):
LI Song-Feng; DENG Guang-Da; LIU Jing-Hua; MA Yan; LU Hai
Beijing Tongren Eye Center,Beijing Tongren Hospital，Capital Medical University，Beijing 100730，China
关键词:
Coats病; 视网膜下液引流; 抗血管内皮生长因子
Keywords:
Coats disease; subretinal fluid drainage; anti-vascular endothelial growth factor
分类号:
R774
DOI:
10.13389/j.cnki.rao.2017.0144
文献标志码:
A
摘要:
目的　研究视网膜下液引流联合玻璃体内注射抗血管内皮生长因子药物雷珠单抗治疗重度渗出性视网膜脱离Coats病的效果。方法　选取2013年4月至2017年1月在北京同仁医院眼科中心确诊为3B期Coats病的患者13例13眼纳入研究。13例患者中，视力为无光感1例，光感～数指7例，0.01～0.1者2例，因年幼无法配合检查3例。巩膜外放液选取位置在视网膜脱离较高的位置，在显微镜观察下缓慢放出视网膜下液，所有患眼放液后于角膜缘后3.5 mm睫状体平坦部行玻璃体内注射抗血管内皮生长因子药物雷珠单抗0.5 mg(0.05 mL)。随访期观察患者的视力、眼压、裂隙灯、间接检眼镜及彩色眼底像。分析异常血管变化，视网膜下液及渗出的吸收情况，视网膜复位及并发症发生情况。结果　13例患者中3例进行了2次的视网膜下液引流，10例进行了1次的视网膜下液引流；联合两次玻璃体内注射雷珠单抗的有6例，联合三次注射的4例，三次以上3例。所有患者的视网膜下液吸收或者大部分吸收后，进行了视网膜冷冻或激光治疗，单纯激光治疗的有5例，单纯视网膜冷冻治疗的3例，激光联合冷冻治疗的5例。13例患者中，视力提高的2例，无变化的8例，因年幼无法配合检查3例。在随访中，8例视网膜完全复位，未观察到与视网膜下液引流和眼内注药手术操作相关的并发症，如眼内炎、视网膜裂孔、玻璃体积血等。结论　视网膜下液引流联合玻璃体内注射雷珠单抗是一种有效治疗重度3B期Coats病的方法。
Abstract:
Objective　To investigate the effects of subretinal fluid drainage combined with intravitreal anti-vascular endothelial growth factor (VEGF) drugs in the treatment of severe exudative retinal detachment Coats disease.Methods　Thirteen patients (13 eyes) with 3B Coats’ disease diagnosed at the Eye Center of Tongren Hospital were included in the study.The participants were aged from 1 year to 11 years with a mean age of (4.15±2.99)years.The visual acuity was no light perception in 1 case,from light perception to counting finger in 7 cases,from 0.01 to 0.1 in 2 cases,and could not be measured due to young in 3 cases.Patients underwent retinal fluid drainage combined with intravitreal ranibizumab (IVR,0.5 mg,0.05 mL) at the pars plana of ciliary body,and with retinal laser photocoagulation or cryotherapy according to the retinal peripheral vascular activity.During the follow-up,the visual acuity,intraocular pressure,slit lamp,indirect ophthalmoscope and color ophthalmoscope were examined and observed.The abnormal blood vessel change,absorption of subretinal fluid,retinal reattachment and complication were observed.Results　Two subretinal fluid drainage were performed in 3 cases,one subretinal fluid drainage in 10 cases.Six cases were combined with two intravitreal injections,4 cases with three intravitral injection,3 cases with intravitreal injection for more than three times.Five cases were treated with simple photocoagulation,3 cases with simple retinal cryotherapy,and 5 cases with laser combined with cryotherapy.In 13 patients,the visual acuity was improved in 2 cases,unchanged in 8 cases,and could not be measured due to young in 3 cases.Eight cases had complete retinal reattachment.No significant postoperative complications occurred during follow-up,such as endophthalmitis,retinal hole and vitreous hemorrhage.Conclusion　Subretinal fluid drainage combined with intravitreal injection is an effective method for severe 3B stage Coats disease.

参考文献/References:

［1］　SHIELDS JA，SHIELDS CL，HONAVAR SG，DEMIRCI H.Clinical variations and complications of Coats disease in 150 cases：the 2000 Sanford Gifford memorial lecture［J］.Am J Ophthalmol，2001，131(5)：561-571.
［2］　SHIELDS JA，SHIELDS CL，HONAVAR SG，DEMIRCI H，CATER J.Classification and management of Coats disease：the 2000 Proctor Lecture［J］.Am J Ophthalmol，2001，131(5)：572-583.
［3］　SUN Y，JAIN A，MOSHFEGHI DM.Elevated vascular endothelial growth factor levels in Coats disease：rapid response to pegaptanib sodium［J］.Graefes Arch Clin Exp Ophthalmol，2007，245(9)：1387-1388.
［4］　KASE S，RAO NA，YOSHIKAWA H，FUKUHARA J，NODA K，KANDA A，et al.Expression of vascular endothelial growth factor in eyes with Coats’ disease［J］.Invest Ophthalmol Vis Sci，2013，54(1)：57-62.
［5］　HE YG，WANG H，ZHAO B，LEE J，BAHL D，MCCLUSKEY J.Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab［J］.Graefes Arch Clin Exp Ophthalmol，2010，248(10)：1519-1521.
［6］　JUN JH，KIM YC，KIM KS.Resolution of severe macular edema in adult Coats’ disease with intravitreal triamcinolone an bevacizumab injection［J］.Korean J Ophthalmol，2008，22(3)：190-193.
［7］　GLER EJ，RANDOLPH JC，CALZADA JI，WILSON MW，HAIK BG.Current management of Coats disease［J］.Surv Ophthalmol，2014，59(1)：30-46.
［8］　KAUL S，UPARKAR M，MODY K，WALINJKAR J，KOTHARI M，NATARAJAN S.Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats disease in children［J］.Indian J Ophthalmol，2010，58(1)：76-78.
［9］　WELLS JR，RD HG.The effect of intravitreal bevacizumab in the treatment of Coats disease in children［J］.Retina，2011，31(2)：617.
［10］　RAMASUBRAMANIAN A，SHIELDS CL.Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction［J］.Br J Ophthalmol，2012，96(3)：356.

相似文献/References:

[1]杨欣悦,王晨光,苏冠方.Coats病的诊断与治疗进展[J].眼科新进展,2017,37(2):196.[doi:10.13389/j.cnki.rao.2017.0051]
　YANG Xin-Yue,WANG Chen-Guang,SU Guan-Fang.Recent advances in diagnosis and treatment of Coats disease[J].Recent Advances in Ophthalmology,2017,37(6):196.[doi:10.13389/j.cnki.rao.2017.0051]
[2]毛新帮,游志鹏,彭灵,等.玻璃体内注射雷珠单抗联合激光光凝治疗Coats病的疗效观察[J].眼科新进展,2017,37(3):259.[doi:10.13389/j.cnki.rao.2017.0065]
　MAO Xin-Bang,YOU Zhi-Peng,PENG Ling,et al.Intravitreal lucentis injections combined with laser photocoagulation for Coats disease[J].Recent Advances in Ophthalmology,2017,37(6):259.[doi:10.13389/j.cnki.rao.2017.0065]

备注/Memo

备注/Memo:
首都临床特色应用研究项目（编号：Z141107002514029）
更新日期/Last Update: 2017-06-28